Capricor Therapeutics Inc. (NASDAQ: CAPR)
$12.9500
-0.1200 ( -0.39% ) 214.3K
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Market Data
Open
$12.9500
Previous close
$13.0700
Volume
214.3K
Market cap
$576.10M
Day range
$12.6250 - $13.3240
52 week range
$3.5200 - $23.4000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | Apr 24, 2024 |
| def | Proxies and info statements | 19 | Apr 01, 2024 |
| ars | Annual reports | 1 | Apr 01, 2024 |
| pre | Proxies and info statements | 18 | Mar 20, 2024 |
| 10-k | Annual reports | 65 | Mar 11, 2024 |
| 8-k | 8K-related | 16 | Feb 29, 2024 |
| 8-k | 8K-related | 12 | Jan 11, 2024 |
| 4 | Insider transactions | 1 | Jan 04, 2024 |
| 4 | Insider transactions | 1 | Jan 04, 2024 |
| 4 | Insider transactions | 1 | Jan 04, 2024 |